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Abstract
Background: The level of expression of functional a7-containing nicotinic acetylcholine receptors (nAChRs) in hippocampal
CA1 pyramidal neurons is believed to be very low compared to hippocampal CA1 interneurons, and for many years this
expression was largely overlooked. However, high densities of expression of functional a7-containing nAChRs in CA1
pyramidal neurons may not be necessary for triggering important cellular and network functions, especially if activation of
a7-containing nAChRs occurs in the presence of positive allosteric modulators such as PNU-120596.
Methodology/Principal Findings: An approach previously developed for a7-containing nAChRs expressed in
tuberomammillary neurons was applied to investigate functional CA1 pyramidal a7-containing nAChRs using rat coronal
hippocampal slices and patch-clamp electrophysiology. The majority (,71%) of tested CA1 pyramidal neurons expressed
low densities of functional a7-containing nAChRs as evidenced by small whole-cell responses to choline, a selective
endogenous agonist of a7 nAChRs. These responses were potentiated by PNU-120596, a novel positive allosteric modulator
of a7 nAChRs. The density of functional a7-containing nAChRs expressed in CA1 pyramidal neurons (and thus, the
normalized net effect of activation, i.e., response net charge per unit of membrane capacitance per unit of time) was
estimated to be ,5% of the density observed in CA1 interneurons. The results of this study demonstrate that despite low
levels of expression of functional pyramidal a7-containing nAChRs, physiological levels of choline (,10 mM) are sufficient to
activate these receptors and transiently depolarize and even excite CA1 pyramidal neurons in the presence of PNU-120596.
The observed effects are possible because in the presence of 10 mM choline and 1–5 mM PNU-120596, a single opening of
an individual pyramidal a7-containing nAChR ion channel appears to transiently depolarize (,4 mV) the entire pyramidal
neuron and occasionally trigger action potentials.
Conclusions: 1) The majority of hippocampal CA1 pyramidal neurons express functional a7-containing nAChRs. In the
absence of PNU-120596, a positive allosteric modulator of a7 nAChRs, a lack of responsiveness of some hippocampal CA1
pyramidal neurons to focal application of 0.5–1 mM choline does not imply a lack of expression of functional a7-containing
nAChRs in these neurons. Rather, it may indicate a lack of detection of a7-containing nAChR-mediated currents by patch-
clamp electrophysiology. 2) PNU-120596 can serve as a powerful tool for detection and enhancement of responsiveness of
low densities of functional a7-containing nAChRs such as those present in hippocampal CA1 pyramidal neurons. 3) In the
presence of PNU-120596, physiological concentrations of choline activate functional CA1 pyramidal a7-containing nAChRs
and produce step-like currents that cause repetitive step-like depolarizations, occasionally triggering bursts of action
potentials in CA1 pyramidal neurons. Therefore, the results of this study suggest that in the presence of PNU-120596 and
possibly other positive allosteric modulators, endogenous choline may persistently activate CA1 pyramidal a7-containing
nAChRs, enhance the excitability of CA1 pyramidal neurons and thus act as a potent therapeutic agent with potential
neuroprotective and cognition-enhancing properties.
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Introduction
The hippocampus is a brain region that supports essential
cognitive functions and memory formation [1]. Hippocampal CA1
pyramidal neurons are important for learning, short-term memory
and memory consolidation [2,3,4] and are particularly vulnerable
to neurodegenerative processes associated with Alzheimer’s
disease, aging, brain trauma and cerebral ischemia [5,6,7,8].
Moreover, the excitability of CA1 pyramidal neurons may
positively correlate with cognitive performance, and has been
shown to decline with age likely due to an age-dependent
enhancement of inhibitory effects of Ca
2+-dependent potassium
conductances [9,10,11]. Therefore, therapeutic approaches that
provide neuroprotection and restore excitability of hippocampal
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13964CA1 pyramidal neurons may benefit patients with various forms of
dementia and brain trauma.
The hippocampus receives cholinergic inputs from the
basal forebrain and expresses multiple pre- and postsynaptic
nAChR subunits [12,13]. Nicotine and other nicotinic agents
including selective a7 nAChR agonists have been shown to
provide neuroprotection and reduce cognitive decline associated
with Alzheimer’s disease, schizophrenia, brain trauma and
aging [9,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31].
Although the majority of hippocampal neurons express a7-
containing (i.e., a7*) nAChR subunits [32], functional hippocam-
pal a7* nAChRs are less common. In fact, for many years the
expression of functional a7* nAChRs in hippocampal CA1
pyramidal neurons was largely overlooked. Although functional
nAChRs have been detected on both excitatory (i.e., glutamater-
gic) and inhibitory (i.e., GABAergic) pre-synaptic terminals,
postsynaptic functional a7* nAChRs were initially believed to be
expressed largely on the inhibitory GABAergic interneurons and
not on the principal pyramidal neurons [33,34,35,36]. This
position has recently been challenged by at least two studies
where whole-cell responses of CA1–3 pyramidal neurons to ACh
or nicotine were detected in electrophysiological and fluorescent
Ca
2+ imaging experiments in hippocampal slices [37,38]; and
activation of post-synaptic, likely dendritic, a7* nAChRs in CA1
pyramidal neurons supported long term potentiation [38]. A
failure of early studies to consistently detect a7* nAChR-mediated
responses in CA1 pyramidal neurons may be explained by the
relatively low density of expression and a potential distal/dendritic
location of functional pyramidal a7* nAChRs.
PNU-120596, a novel positive allosteric modulator of a7*
nAChRs, increases the potency of nicotinic agonists [39,40,41,
42,43] enhancing the responsiveness of functional a7* nAChRs
and producing therapeutic benefits in animal models [40]. In rats,
intravenous injections of 1 mg/kg PNU-120596 elevated the
concentration of PNU-120596 in the cerebrospinal fluid to
,1.5 mM [40]. This value falls near the EC50 for potentiating
effects of PNU-120596 (EC50,1.5 mM) [44,45]. Concentrations
slightly lower than the EC50 (i.e., 1 mM PNU-120596) have been
shown to enhance the effects of sub-threshold concentrations of
choline, a selective endogenous agonist of a7* nAChRs, allowing
physiological levels of choline (i.e., 5–10 mM) to become effective
in activation of native a7* nAChRs in the absence of exogenous
nicotinic agents [43]. Although choline is found in the cerebro-
spinal fluid in in vivo preparations at concentrations near 5–10 mM
[46,47,48,49,50,51,52,53], isolated brain slices are likely choline-
depleted and may contain only sub-mM levels of choline
(V. Uteshev, R. Papke and L. Prokai, unpublished). Therefore,
to model the effects of endogenous choline on CA1 pyramidal
a7* nAChRs in hippocampal slices, physiological concentrations
of choline (i.e., ,10 mM) need to be added to artificial
cerebrospinal fluid (ACSF).
Additional challenges for detection of whole-cell a7* nAChR-
mediated responses arise from the extremely short mean open time
(,100 ms) of individual a7* nAChR ion channels [54]. Therefore,
to produce a clearly detectable whole-cell current, activation of
individual a7* nAChRs has to be well-synchronized which may be
difficult to achieve in whole-cell experiments in brain slices. PNU-
120596 has been shown to increase the mean open time of a7
nAChR ion channels without producing significant changes in ion
channel selectivity, Ca
2+ permeability and single channel conduc-
tance [40]. PNU-120596 does not activate native functional a7*
nAChRs in the absence of nicotinic agonists [43], instead, it lowers
the energy barrier and allows lower concentrations of nicotinic
agonists to activate a7* nAChRs [55]. When administered alone
intravenously, low concentrations of PNU-120596 (i.e., 0.1–
1.5 mM) were effective in reversing the amphetamine-induced
auditory gating deficit in rats [40] likely via potentiating the effects
of endogenous choline on native a7* nAChRs.
The concentration of endogenous choline (i.e., 5–10 mM) in the
cerebrospinal fluid (CSF) is too low to activate native a7* nAChRs
[43,56], especially in hippocampal CA1 pyramidal neurons where
expression of a7* nAChRs appears limited [33,34,38]. Therefore,
choline is not usually considered an effective therapeutic agent.
However, recently this laboratory has proposed that in the presence
of PNU-120596, 5–10 mM choline may become effective in
producing a weak but persistent activation of a7* nAChRs in
hypothalamic tuberomammillary (TM) neurons known to express
high densities of functional a7* nAChRs [43]. In addition to
producing a weak persistent activation, synergistic action of 1 mM
PNU-120596 plus 5–10 mM choline generated whole-cell responses
that were reminiscent of and postulated to be single a7* nAChR ion
channel openings detectable in whole-cell patch-clamp configura-
tion [43]. Since in the presence of PNU-120596, a single opening of
a7* nAChR ion channel was sufficient for significant depolarization
and even excitation of the entire TM neuron, high densities of
expression of functional a7* nAChRs may not be necessary for a
considerable enhancement of excitability of a7* nAChR-expressing
neurons under similar conditions. The present study tests the
hypothesis that the majority of hippocampal CA1 pyramidal
neurons express functional a7* nAChRs although at relatively low
densities compared to TM neurons or hippocampal CA1 interneu-
rons.Secondly,thisstudy demonstrates thatinthe presenceofPNU-
120596, physiological levels of choline produce a weak persistent
activation of CA1 pyramidal a7* nAChRs and enhance excitability
of hippocampal CA1 pyramidal neurons. This weak persistent
activation of a7* nAChRs may be neuroprotective [9,14,16,22,57]
and cognitively beneficial [15,23,25,26,27,28,29,58].
Materials and Methods
Animals
Young adult male and female Sprague-Dawley rats (P18–30)
were used in experiments. Hippocampal slices from male and
female rats were found to be consistently similar and expressed
functional a7* nAChRs withsimilar properties. However, this study
did not specifically investigate gender dependence of functional a7*
nAChRs in the hippocampus. Animal care was in accordance with
the Guide for the Care and Use of Laboratory Animals (NIH 865-
23, Bethesda, MD). Full details of the study were approved by the
Animal Care and Use Committee of Southern Illinois University
(Protocols 197-06-011 and 197-07-018).
Preparation of brain slices
To exclude potential drug interference, general or local
anesthetics were not used and animals were euthanized via a
rapid decapitation. Brains were rapidly removed and transferred
to an ice-cold sucrose-rich solution of the following composition (in
mM): sucrose 250, KCl 3, NaH2PO4 1.23, MgCl2 5, CaCl2 0.5,
NaHCO3 26, glucose 10 (pH 7.4), when bubbled with carbogen
(95% O2 and 5% CO2). Three to four coronal whole-brain slices
(260 mm thick) containing the hippocampus were cut in a sucrose-
rich solution at 3uC using Vibratom-1000+ (Vibratom, St. Louis,
MO). Slices were transferred to a temporary storage chamber
where they were maintained for ,30 min at 30uCi na n
oxygenated artificial cerebral-spinal fluid (ACSF) of the following
composition (in mM): NaCl 125, KCl 3, NaH2PO4 1.23, MgCl2 1,
CaCl2 2, NaHCO3 26, glucose 10 (pH 7.4), when bubbled with
carbogen. Slices were then transferred back into the storage
CA1 Pyramidal a7 nAChRs
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carbogen. The majority of experiments were conducted within
,6 hours after the tissue preparation. However, experiments
occasionally lasted longer than expected and slices were incubated
in carbogenated ACSF for up to 10 hours. Regardless of the
duration of incubation, if slices and/or neurons showed signs of
damage (e.g., slices lost their original shape, texture or color; or
neurons became granulated, shapeless or borderless with clearly
seen nuclei), then slices were discarded and a new tissue preparation
was conducted or the work was postponed until the next day.
Drugs
PNU-120596 (N-(5-Chloro-2,4-dimethoxyphenyl)-N’-(5-methyl-
3-isoxazolyl)-urea) was purchased from Tocris Bioscience (Ellis-
ville, MO). Gabazine (6-Imino-3-(4-methoxyphenyl)-1(6H)-pyrida-
zinebutanoic acid hydrobromide), DNQX (6,7-dinitroquinoxa-
line-2,3-dione), AP-5-Na
+ (DL-2-Amino-5-phosphonopentanoic
acid sodium salt) and tetrodotoxin (TTX) were purchased from
Ascent Scientific (Bristol, UK). Other chemicals were purchased
from Sigma-Aldrich (St. Louis, MO). Choline-containing solutions
were freshly made immediately prior to each experiment from a
1 M choline stock solution which was kept frozen at 220uC.
Previous studies reported that, in heterologous systems, the EC50
for potentiating effects of PNU-120596 was near 1.5 mM [44,45].
Therefore, in the present study, 2 mM and 5 mM PNU-120596
were tested. These concentrations of PNU-120596 may be
therapeutically relevant because intravenous administration of
1 mg/kg PNU-120596 has been shown to elevate the concentra-
tion of PNU-120596 in the brains of rats to similar values
(,1.5 mM) producing therapeutically beneficial effects [40].
In the majority of experiments, ACSF contained the following
antagonists to inhibit GABAA, AMPA, NMDA, muscarinic ACh
and GABAA/glycine receptors, respectively: 20 mM gabazine,
15 mM DNQX, 50 mM AP-5, 10 mM atropine and 40 mM
picrotoxin. In voltage-clamp experiments, 0.3 mM TTX was
typically added to ACSF to inhibit voltage-gated sodium ion
channels.
Patch-clamp recordings
For patch-clamp experiments, slices were transferred to the
recording chamber perfused with ACSF at a rate of 1 ml/min
using a perfusion pump 2232 Microperpex S (LK.B, Upsalla,
Sweden). Hippocampal CA1 pyramidal neurons and CA1
interneurons were selected under visual control using an infrared
Olympus BX-51WI microscope (Olympus America Inc, Center
Valley, PA). Electrophysiological patch-clamp recordings were
made using a MultiClamp-700B amplifier equipped with Digi-
data-1440A A/D converter (Molecular Devices, Sunnyvale, CA).
Data were filtered at 4–8 kHz, sampled at 20–50 kHz and stored
on a personal computer for offline analysis. For recordings, patch
pipettes were pulled using a Sutter P-97 horizontal puller (Sutter
Instruments, Novato, CA). The pipette resistance was ,4–6 MV
when filled with the internal solution (see below). After formation
of a stable gigaseal (.2G V), the whole-cell configuration was
established. Choline (0.5–1 mM) was applied via picospritzer
pipettes (application pressure 5–8 psi, Parker Hannifin Instru-
mentation, Cleveland, OH, USA) identical to those used for patch-
clamp recordings. The tip of application pipette was positioned
,15 mm from the recorded neuron. PNU-120596 (1–5 mM) was
applied to ACSF. Whole-cell recordings were conducted at room
temperature. The membrane voltage in voltage-clamp experi-
ments was -60 mV, unless otherwise specified. The extracellular
solution was identical to ACSF which was used for the brain tissue
preparation. The intracellular electrode solution contained
(in mM): K-gluconate 140, NaCl 1, MgCl2 2, Mg-ATP 2, Na-
GTP 0.3, HEPES 10, KOH 0.42 (pH 7.38). To reduce the
recording noise, in experiments where responses of a7* nAChRs
in CA1 pyramidal neurons and CA1 interneurons were compared,
a Cs-methanesulfonate-based internal solution was used with the
following composition (in mM): CsMeSO3 140, NaCl 6, MgCl2 2,
Mg-ATP 2, Na-GTP 0.3, HEPES 10, CsOH 0.3 (pH 7.38).
Membrane voltages were not corrected for the liquid junction
potentials: VLJ(K-gluconate)=16.2 mV and VLJ(CsMeSO3)
=9.8 mV. When necessary, a GENIE Plus syringe pump (Kent
Scientific, Torrington, CT) was used to add 0.3 mM tetrodotoxin
(TTX, a Na
+ ion channel antagonist) or 20 nM methyllycaconi-
tine (MLA, a selective a7 nAChR antagonist) to the ACSF just
before it entered the recording chamber. The final drug
concentrations in the chamber were then calculated based on
the known concentrations of drug stock solutions and adjustable
rates of all pumps. The application solutions containing various
concentrations of choline were prepared fresh daily.
Analysis
The analysis of current-deviations and action potentials was
conducted using Clampfit-10.1 software program. A threshold
search event detection protocol (Clampfit-10.1) was used to
evaluate the frequencies of step-like current deviations and action
potentials. To measure current net charge, choline and PNU-
120596 were added to ACSF for at least 20 min and step-like
responses of hippocampal CA1 pyramidal neurons in rat brain
slices were continuously recorded in voltage-clamp in 10 min
intervals and analyzed offline. The experimental results are
presented as the mean 6 S.D., unless otherwise indicated. Curve
fitting was done using ProStat analysis program (Poly Software
International, Pearl River, NY).
Results
Patch-clamp electrophysiological recordings were conducted
using coronal hippocampal slices of young adult rats to test and
confirm the hypothesis that in the presence of PNU-120596,
physiological concentrations of choline (i.e., ,10 mM) are effective
in eliciting a weak but persistent activation of functional
hippocampal CA1 pyramidal a7* nAChRs and that high densities
of expression of these receptors are not required to cause
significant effects on excitability of hippocampal CA1 pyramidal
neurons. The majority of experiments were conducted in the
absence of glutamatergic, gabaergic/glycinergic and muscarinic
AChR-mediated inputs. A total of 321 hippocampal CA1
pyramidal neurons and 72 hippocampal interneurons were
studied. The recorded neurons were identified by their morphol-
ogy and location within the slice. Specifically, hippocampal CA1
pyramidal neurons had a distinct pyramidal shape (Figure 1A) and
were located in the CA1 Stratum Pyramidale region of the
hippocampus (Figure 1A). Typically, these neurons did not exhibit
robust responsiveness to pressure-applied 0.5–1 mM choline in
voltage-clamp whole-cell experiments (Figure 1C–D). By contrast,
hippocampal CA1 interneurons had a more rounded shape
(Figure 1B) and were located in the CA1 Stratum Radiatum region of
the hippocampus (Figure 1B). Typically, these neurons responded
to pressure-applied 0.5–1 mM choline with robust currents in
voltage-clamp whole-cell experiments (see below and [33,35]).
Expression of native functional a7* nAChRs in
hippocampal CA1 pyramidal neurons
In the initial set of whole-cell experiments, 0.5–1 mM choline, a
selective endogenous agonist of a7 nAChRs, was focally
CA1 Pyramidal a7 nAChRs
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neurons via a picospritzer pipette identical to that used for
patch-clamp recordings. In these experiments, the tip of
application pipette was positioned within ,15 mm from the
recorded cell soma (white arrows, Figure 1A) and brief (1–2 s)
puffs of choline were delivered every 2–3 min. Pressure-applied
0.5–1 mM choline (,5 psi pressure) elicited either no responses
(Figure 1C) or small whole-cell currents (,30 pA in amplitude,
Figure 1D). In this study, pressure-applied 0.5–1 mM choline
produced detectable responses (i.e., current peak/noise .0.5) in
52 out of 73 tested CA1 pyramidal neurons (,71%) (e.g.,
Figure 1D). The remaining 21 neurons (,29%) did not respond to
0.5–1 mM choline by clearly detectable current deviations (e.g.,
Figure 1C).
As expected, addition of 1–5 mM PNU-120596 to ACSF
potentiated responses of CA1 pyramidal neurons to pressure-
applied 0.5–1 mM choline (Figure 1E). These responses were
completely and reversibly blocked by 20 nM methyllycaconitine
(MLA; n=11), a selective antagonist of a7 nAChRs (Figure 1F–
G), supporting the involvement of functional CA1 pyramidal a7*
nAChRs. In the presence of PNU-120596, some whole-cell
current deviations were step-like (arrows, Figure 1E) and
reminiscent of openings of individual ion channels as reported
previously for hypothalamic tuberomammillary a7* nAChRs [43].
To quantify these effects an identical experimental protocol was
used in four CA1 pyramidal neurons (a-d; Figure 1H): (a) 0.5 mM
choline was pressure-applied 3–4 times in the absence of PNU-
120596; (b) PNU-120596 (1 mM) was then added to ACSF for at
least 50 min and responses to pressure-applied 0.5 mM choline
were recorded again; (c) MLA (20 nM) was then applied to ACSF
for ,15 min resulting in a complete block of choline-evoked
responses and (d) MLA was removed from ACSF resulting in a
partial reversal of responses after ,50 min of washout. Net charge
of step-like currents over the first 10 s after the beginning of
choline puff was measured for each of the four cells tested, the
results were averaged and plotted (Figure 1H). Addition of 1 mM
PNU-120596 to ACSF significantly enhanced responses of
hippocampal CA1 pyramidal neurons to pressure-applied
0.5 mM choline (p,0.017; n=4; Figure 1H, columns (a,b)). All
net charge values (i.e., b–d) in each given experiment were
normalized to net charge of the control response (i.e., a).
In some cases, a lack of responses of CA1 pyramidal neurons to
focal administration of 0.5–1 mM choline (Figures 2A and 2D) may
have reflected an inability of whole-cell patch-clamp recordings to
detect a7* nAChR-mediated currents in hippocampal CA1
pyramidal neurons in slices rather than a lack of expression of
functional a7* nAChRs in these neurons. To test this hypothesis, 1–
5 mM PNU-120596 was added to ACSF in experiments where CA1
pyramidal neurons did not respond to 0.5–1 mM choline
(Figures 2A and 2D). Indeed, 17 out of 18 tested CA1 pyramidal
neurons that did not initially respond to pressure-applied choline
(Figures 2A and 2D) began responding to choline after addition of
PNU-120596 to ACSF (Figures 2B and 2E).
To quantify these effects, an identical experimental procedure
was used in six experiments in which in the absence of PNU-
120596 hippocampal CA1 pyramidal neurons did not respond to
pressure-applied 0.5 mM choline (e.g., Figures 2A and 2D).
Addition of 1 mM PNU-120596 to ACSF enhanced the respon-
siveness of a7* nAChRs expressed in these neurons resulting in
step-like responses (e.g., Figures 2B and 2E). Current net charge
over the first 10 s after the beginning of choline puff was measured
and plotted for three experimental phases: (a) in the absence of
PNU-120596; (b) ,24 min after addition of PNU-120596 to
ACSF; and (c) ,45 min after addition of 1 mM PNU-120596 to
ACSF (Figure 2C). Net charge values measured at ,24 min and
,45 min after PNU-120596 administration were significantly
different (p,0.02, n=6; Figure 2C). Potentiated responses were
also completely and reversibly blocked by 20 nM MLA (n=3;
Figure 2E–G). These results demonstrated that a lack of
responsiveness of CA1 pyramidal neurons to 0.5 mM choline
does not necessarily reflect a lack of expression of functional a7*
nAChRs.
The responses of hippocampal CA1 pyramidal a7* nAChRs to
0.5–1 mM choline were resistant to 0.3 mM TTX, 20 mM
gabazine, 15 mM DNQX, 50 mM AP-5, 10 mM atropine and
40 mM picrotoxin which were routinely added to ACSF to inhibit
Na
+ voltage-gated ion channels, GABAA, AMPA, NMDA,
muscarinic ACh and GABAA/glycine receptors, respectively.
These initial voltage-clamp experiments used focal pressure
application of relatively high concentrations of choline (0.5–1 mM)
to demonstrate that: 1) Hippocampal CA1 pyramidal neurons
express functional a7* nAChRs as previously reported [37,38];
and 2) A lack of responsiveness of some hippocampal CA1
pyramidal neurons to focal application of 0.5–1 mM choline in the
absence of PNU-120596 does not imply a lack of expression of
functional a7* nAChRs in these neurons. Rather, it may indicate a
lack of detection of a7* nAChR-mediated currents by patch-clamp
electrophysiology.
Comparison of the net effects of activation of native
functional a7* nAChRs in CA1 pyramidal neurons and
CA1 interneurons
The densities of expression and thus, the normalized net effect
of activation (i.e., response net charge per unit of membrane
capacitance per unit of time) of native functional a7* nAChRs in
CA1 pyramidal neurons and CA1 interneurons were compared in
whole-cell patch-clamp experiments in hippocampal slices. To
improve the detectability of responses of pyramidal a7* nAChRs
to choline, 5 mM PNU-120596 was added to ACSF. In these
experiments, 0.5 mM choline was pressure-applied via picosprit-
Figure 1. Responses of hippocampal CA1 pyramidal neurons to pressure-applied choline in the absence and presence of PNU-
120596. In hippocampal slices, CA1 pyramidal neurons (A) can be easily distinguished from interneurons (B) based on their location and shape.
White arrows indicate the positions of the tips of application pipettes (A–B). Usually, CA1 pyramidal neurons do not exhibit robust responsiveness to
choline, a selective endogenous a7 nAChR agonist (C–D). Pressure application of 0.5–1 mM choline to pyramidal neurons elicited detectable whole-
cell responses in 71% of voltage-clamp experiments. Addition of 1 mM PNU-120596 to ACSF considerably enhanced the responsiveness of CA1
pyramidal neurons to choline (E). These responses were completely and reversibly blocked by 20 nM methyllycaconitine (MLA) (F–G). In the presence
of PNU-120596, step-like currents were routinely observed in whole-cell experiments (arrows, E). H) To quantify these effects, in four experiments with
CA1 pyramidal neurons, 0.5 mM choline was pressure-applied 3–4 times in the absence of PNU-120596 (H, a); then 1 mM PNU-120596 was added to
ACSF for at least 50 min and responses to pressure-applied 0.5 mM choline were recorded again (H, b); 20 nM MLA was then added to ACSF for
,15 min resulting in a complete block of choline-evoked responses (H, c); and finally, MLA was removed from ACSF resulting in a partial reversal of
responses after ,50 min of MLA washout (H, d). Net charge of step-like currents was measured over the first 10 s after the beginning of choline puff.
Responses of hippocampal CA1 pyramidal neurons to pressure-applied 0.5 mM choline in the absence (H, a) and presence (H, b)o f1mM PNU-120596
were significantly different (p,0.017; n=4). In each experiment, net charge values were normalized to the net charge of control responses (H, a).
doi:10.1371/journal.pone.0013964.g001
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neurons or CA1 interneurons (Figure 1A–B). Choline was applied
every 3 min during the wash-in phase of 5 mM PNU-120596
added to ACSF. Net charge of responses of pyramidal neurons
(Figure 3A) and interneurons (Figure 3B) was measured over a 20 s
interval from the moment of choline application between the 12
th
and the 51
st min of the PNU-120596 wash-in. If the quality of
recordings declined during this 39 min time window (i.e., 14
individual applications), then, the data were discarded. Net charge
from successful recordings was then normalized to (i.e., divided by)
the neuronal capacitance to account for differences in neuronal
size among tested neurons. The normalized net charge was then
plotted as a function of time from the start of PNU-120596 wash-
in (Figure 3C). The results of these experiments demonstrate that
the density of expression of functional a7* nAChRs in CA1
pyramidal neurons comprises of ,5% (i.e., ,1/20) of the density
of functional a7* nAChRs expressed in CA1 interneurons (n=7;
Figure 3C). This finding implies that the normalized net effects of
activation (i.e., response net charge per unit of membrane
capacitance per unit of time) of a7* nAChRs expressed in CA1
pyramidal neurons is ,20-fold weaker than the net response of
activation of functional a7* nAChRs expressed in CA1 interneu-
rons. In these experiments, ACSF contained 20 mM gabazine,
15 mM DNQX, 50 mM AP-5, 40 mM picrotoxin and 0.3 mM
TTX. The internal solution contained CsMeSO3 (see Methods).
One limitation of this approach is that it does not fully account
for potential differences in the distribution of functional a7*
nAChRs in CA1 pyramidal neurons and CA1 interneurons. For
instance, upon focal pressure application of 0.5 mM choline,
dendritic a7* nAChRs (i.e., distal location relative to the
application tip) will be exposed to a somewhat lower concentration
of choline than somatic a7* nAChRs (i.e., proximal location
relative to the application tip) because of the mostly somatic
position of the application pipette tip (white arrows, Figure 1A–B).
Therefore, in this approach, the contribution of dendritic a7*
nAChRs to the net response may have been somewhat
underestimated.
The effects of physiological levels of choline in the
presence of PNU-120596
Administration of physiological concentrations of choline (i.e.,
,10 mM) to ACSF is a more adequate model of the effects of
endogenous choline and systemic drug administration than focal
pressure application of 0.5–1 mM choline. Administration of
10 mM choline alone to ACSF (n=6; Figure 4A) or 2 mM PNU-
120596 alone to ACSF (n=6; Figure 4C) did not elicit detectable
responses in CA1 pyramidal neurons when the drugs were
administered for over 1 hr. It is worth mentioning that in one
experiment, two step-like current deviations (850 ms and 900 ms
in duration) were detected within 1 min from one another after
,94 min of administration of 2 mM PNU-120596 in the absence
of exogenous choline (not shown). These unusual openings were
attributed to a potential presence in hippocampal slices of
extremely small amounts of endogenous a7* nAChR agonists
(e.g., ACh and/or choline). This rare ion channel activity in the
absence of exogenous choline was not investigated in this study.
By contrast, the addition of 2 mM PNU-120596 to ACSF
containing 10 mM choline (Figure 4B), or the addition of 10 mM
choline to ACSF containing 2 mM PNU-120596 (Figure 4D)
resulted in repetitive step-like current deviations in 13 out of 16
voltage-clamp whole-cell experiments (,81%; Table 1). Step-like
responses were reminiscent of openings of individual ion channels
and were completely and reversibly blocked by 20 nM MLA
supporting the involvement of a7* nAChRs (n=5; Figure 4E–F).
The mean duration, the frequency and the mean net charge of
step-like current deviations are presented in Table 1. To evaluate
net charge, the area under step-like current deviations was
measured over a 10 min interval at least 20 min after adminis-
tration of 2 mM PNU-120596 to ACSF. At the time of application
of PNU-120596, 10 mM choline was already present in ACSF for
at least 20 min.
A similar protocol was used in 12 experiments where 5 mM
PNU-120596 (instead of 2 mM) was added to ACSF containing
10 mM choline and step-like responses were observed in 10 out of
12 voltage-clamp whole-cell experiments (Table 1). In these
experiments, the frequency of step-like current deviations and the
mean net charge (but not the mean open time of current
deviations) were significantly greater than the corresponding
values measured in experiments with 2 mM PNU-120596
(Table 1). These results demonstrate that, in the presence of
PNU-120596, the enhanced responsiveness of pyramidal a7*
nAChRs to choline results from a synergistic action of choline and
PNU-120596 and that the potentiation of 10 mM choline-
mediated responses by PNU-120596 is concentration dependent.
In these experiments, ACSF contained 20 mM gabazine, 15 mM
DNQX, 50 mM AP-5, 10 mM atropine, 40 mM picrotoxin and
0.3 mM TTX.
The current-voltage relationship. To build the current-
voltage relationship of step-like current deviations, 0.5 mM
choline plus 5 mM PNU-120596 were added to ACSF and step-
like responses were recorded in voltage-clamp at various
membrane potentials between 290 mV and +30 mV with a step
of 30 mV (n=6; Figure 4G). The current-voltage relationship was
inwardly rectified and lacked the outward current component
(n=6; Figure 4H), a typical feature of a7* nAChRs in the
presence of external and internal Mg
2+ [59]. These results further
supported the enhanced sustained activation of CA1 pyramidal
a7* nAChRs by 10 mM choline in the presence of PNU-120596.
The effects of 10 mM choline plus 2–5 mM PNU-120596
on the excitability of CA1 pyramidal neurons
IntheabsenceofcholineandPNU-120596,andinthepresenceof
20 mM gabazine, 15 mM DNQX, 50 mM AP-5, 40 mM picrotoxin
and 10 mM atropine, the mean resting potential of hippocampal
CA1 pyramidal neurons was estimated to be 260.062.2 mV
(n=64). Under these conditions, CA1 pyramidal neurons were not
Figure 2. Improved detection of a7* nAChR-mediated currents in hippocampal CA1 pyramidal neurons in the presence of PNU-
120596. In some patch-clamp experiments conducted in hippocampal slices, focal pressure administration of 0.5 mM choline to hippocampal CA1
pyramidal neurons did not elicit detectable whole-cell currents (A and D). Traces A and D were obtained from different CA1 pyramidal neurons. Trace
D is the same as trace C in Figure 1. The same neurons began to respond to choline after addition of 1 mM PNU-120596 to ACSF (B and E). These
responses were completely and reversibly blocked by 20 nM MLA (F–G) supporting the expression of functional a7* nAChRs. C) To quantify these
effects, in six experiments in which in the absence of PNU-120596 hippocampal CA1 pyramidal neurons did not respond to pressure-applied 0.5 mM
choline, addition of 1 mM PNU-120596 to ACSF resulted in robust responses. Current net charge over the first 10 s after the beginning of choline puff
was measured for three experimental phases: (C, a) in the absence of PNU-120596; (C, b) ,24 min after addition of PNU-120596 to ACSF; and (C, c)
,45 min after addition of 1 mM PNU-120596 to ACSF. Net charge values measured at ,24 min and ,45 min after PNU-120596 administration were
significantly different (p,0.02, n=6) indicating time-dependence of PNU-120596 effects within the time range used in these experiments.
doi:10.1371/journal.pone.0013964.g002
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during current-clamp recordings (n=4, Figure 5A). By contrast,
upon administration of 10 mM choline plus 2–5 mM PNU-120596
foratleast20 min,step-likevoltage(Figure5B)orcurrent(Figure5C)
deviations were observed in current- or voltage-clamp experiments,
respectively.TracesshowninFigures5B and5Cwereobtained from
the same CA1 pyramidal neuron in current- and voltage-clamp
configurations, respectively, ,1m i na p a r t .
Figure 3. Comparison of the levels of expression of native functional a7* nAChRs in CA1 pyramidal neurons and CA1 interneurons.
The densities of expression of functional a7* nAChRs in CA1 pyramidal neurons and CA1 interneurons were compared in voltage-clamp whole-cell
experiments in hippocampal slices. PNU-120596 (5 mM) was added to ACSF to enhance the detectability of a7* nAChR-mediated responses. In the
presence of 5 mM PNU-120596 in ACSF, 0.5 mM choline was pressure-applied to CA1 pyramidal neurons or CA1 interneurons via a picospritzer
pipette every 3 min. Representative traces (A–B) illustrate responses that were obtained from CA1 pyramidal neurons (A) and CA1 interneurons (B) 12,
24 and 45 min (framed time marks) after addition of 5 mM PNU-120596 to ACSF. Responses of CA1 pyramidal neurons (A) and interneurons (B) were
analyzed within a time window between the 12
th and the 51
st min after the start of wash-in phase of PNU-120596. Net charge of current responses
from both types of neurons was measured over a 20 s interval from the moment of choline application. Net charge was then normalized to the
neuronal capacitance to account for differences in the neuronal size and plotted as a function of time (C). The results are presented as the mean 6
S.E.M. Open triangles illustrate the data points obtained from CA1 pyramidal neurons (n=7); while open circles represent the data points obtained
from CA1 interneurons (n=7). Closed triangles illustrate values obtained by multiplying the pyramidal response net charge (i.e., open triangles) bya
factor of 20.
doi:10.1371/journal.pone.0013964.g003
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plus 2 mM PNU-120596 added to ACSF for at least 20 min, step-
like voltage deviations triggered action potentials in a7 out of 24
(,29%) CA1 pyramidal neurons tested (Figure 5D). In the
remaining 17 cells, step-like voltage-deviations did not trigger
action potentials (Figure 5B). Traces shown in Figures 5D and 5E
Figure 4. Responses of hippocampal CA1 pyramidal neurons to physiological concentrations of choline in ACSF in the presence of
2 mM PNU-120596. Physiological concentrations of choline alone (i.e., 10 mM; A) or 2 mM PNU-120596 alone (C) added to ACSF, did not elicit
responses in CA1 pyramidal neurons in voltage-clamp whole cell experiments. By contrast, addition of 2 mM PNU-120596 to ACSF (containing 10 mM
choline) for at least 20 min (B), or addition of 10 mM choline to ACSF (containing 2 mM PNU-120596) for at least 20 min (D) elicited repetitive step-like
current deviations completely and reversibly inhibited by 20 nM MLA (E–F). The current-voltage relationship (n=6) built for step-like current
deviations was inwardly rectified and lacked the outward component – a typical property of a7* nAChRs (G–H).
doi:10.1371/journal.pone.0013964.g004
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and voltage-clamp configurations, respectively, ,1 min apart.
When 10 mM choline plus 5 mM PNU-120596 were added to
ACSF, action potentials were triggered by step-like voltage
deviations in over twice as many CA1 pyramidal neurons: 12
out of 17 (,70.6%) cells tested (Figure 5F). The average number of
action potentials elicited by step-like voltage-deviations was
estimated to be 6.866.0 APs/min (n=7) in the presence of
10 mM choline plus 2 mM PNU-120596 and 24.5618.0 APs/min
(n=10) in the presence of 10 mM choline plus 5 mM PNU-120596
(Table 1) – a statistically significant difference (p,0.025). Traces
shown in Figures 5F and 5G were obtained from the same CA1
pyramidal neuron in current- and voltage-clamp configurations,
respectively, ,1 min apart.
These results demonstrate that in the presence of PNU-120596
in ACSF, individual openings of a7* nAChR ion channels appear
to be detectable in whole-cell voltage- and current-clamp
recordings as step-like current and voltage deviations, respectively.
In current-clamp experiments, these putative single channel
openings resulted in small repetitive step-like depolarizations that
can occasionally excite hippocampal CA1 pyramidal neurons.
Therefore, in the presence of PNU-120596, physiological
concentrations of choline appear to enhance the excitability of
CA1 pyramidal neurons and these effects are concentration-
dependent.
Evaluation of the first latency time and wash-out rates of
the effects of choline plus PNU-120596 applied to ACSF
The first latency time (i.e., time between the start of drug
application to ACSF and the first step-like current deviation) was
6.861.6 min (n=6) upon addition of 5 mM PNU-120596 to
ACSF that contained 0.5 mM choline for at least 30 min. The first
latency time was 3.160.2 min (n=4) upon addition of 0.5 mM
choline to ACSF that contained 5 mM PNU-120596 for at least
30 min. Therefore, the onset of effects of 0.5 mM choline (in the
continued presence of 5 mM PNU-120596) was approximately
2.2-fold faster than the onset of effects of 5 mM PNU-120596 (in
the continued presence of 0.5 mM choline). The first latency times
likely reflected the method of drug administration employed in this
study (drugs were added to ACSF), the speed of ACSF perfusion
(1 ml/min), the volume of the recording chamber (,2 ml), the
location of recorded neurons within the slice and the location of
slices within the recording chamber. However, the 2.2-fold
difference in the first latency times for wash-in of choline and
PNU-120596 likely reflected differences in the rates of equilibra-
tion of these drugs in hippocampal tissues and was determined by
the drug lipophilicity, molecular size, diffusion coefficient, receptor
binding properties and other biophysical properties.
To determine the washout rates of choline and PNU-120596,
0.5 mM choline plus 5 mM PNU-120596 were added to ACSF for
,1 hour to elicit repetitive step-like responses in voltage-clamp
experiments (Figures 6Aa and 6Ca). Choline or PNU-120596 was
then removed from ACSF one at a time, while the other
compound remained in ACSF. As the effects of choline plus
PNU-120596 were synergistic (Figure 4A–D), a removal of either
of the two components led to a reduction in the frequency of step-
like current deviations (Figures 6Ab-c and 6Cb-c). The frequency
of step-like responses was measured in events per minute and
plotted as a function of time (Figures 6B and 6D). The data were
fitted with single exponential functions and the decay time
constants were determined. The washout time constant of 5 mM
PNU-120596 (in the continued presence of 0.5 mM choline in
ACSF) was 25.9 min (n=5; Figure 6B; an exponential fit
(R
2=0.93): y=0.88exp(20.04 t); whereas the washout time
constant of 0.5 mM choline (in the continued presence of 5 mM
PNU-120596 in ACSF) was 9.9 min (n=5; Figure 6D; an
exponential fit (R
2=0.93): y=1.07exp(20.10 t), where t is the
washout time in minutes. Therefore, the washout of 0.5 mM
choline from hippocampal tissue (in the continued presence of
5 mM PNU-120596 in ACSF) was ,2.6-fold faster than the
washout of 5 mM PNU-120596 (in the continuing presence of
0.5 mM choline in ACSF). Thus, the rates of both wash-in and
washout of PNU-120596 appear to be considerably slower than
the rates of wash-in and washout of choline, respectively. Again,
these differences likely reflect differences in the rates of
equilibration of these drugs within hippocampal tissue. In these
experiments, ACSF always contained 20 mM gabazine, 15 mM
DNQX, 50 mM AP-5, 40 mM picrotoxin and 0.3 mM TTX.
Discussion
Deficits in hippocampal a7* nAChR activation are a key
accompanying factor in certain cognitive disorders and enhancing
this activation by nicotinic agonists has been shown to produce
cognitive benefits. Choline is an endogenous selective a7 nAChR
agonist but present in the cerebrospinal fluid (CSF) at much lower
concentrations (,10 mM) relative to its EC50 (i.e., ,0.5–1.5 mM;
[60,61]). Therefore, endogenous choline may not be effective in
activation of native hippocampal CA1 pyramidal a7* nAChRs in
the absence of positive allosteric modulators, such as PNU-
120596. In fact, this is true even for hypothalamic tuberomam-
millary neurons that express much higher densities of a7* nAChRs
[43] than CA1 pyramidal neurons. This conclusion also
complements previous reports demonstrating that choline exhibits
a greater potency for desensitization (IC50 ,40 mM, [56]) than
activation of a7* nAChRs (EC50 ,0.5–1.5 mM; [60,61]). PNU-
120596 reduces desensitization of a7 nAChRs and thus, increases











10 mM choline +2 mM PNU-120596 13 1.160.7 1.8±1.7 9.3±9.6 6.8±6.0
& (n=7)
10 mM choline +5 mM PNU-120596 10 1.060.3 112.2±41.6* 53.4±23.6* 24.5±18.0*
The results of experiments where 10 mM choline plus either 2 mM (top row) or 5 mM PNU-1205096 (bottom row) were applied to ACSF for at least 20 min and step-like
current deviations in voltage-clamp or action potentials in current-clamp were recorded and analyzed. Significant differences were observed among the frequencies
(p=0.0001) and net charge (p=0.0001) of step-like current deviations, but not the mean open time (p.0.67). Significant differences were also observed between the
frequencies of action potentials (p,0.025).
&) Note that in the presence of 10 mM choline plus 2 mM PNU-120596, action potentials were observed in only 7 out of 13 CA1 pyramidal neurons.
doi:10.1371/journal.pone.0013964.t001
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PLoS ONE | www.plosone.org 10 November 2010 | Volume 5 | Issue 11 | e13964Figure 5. Enhanced excitability of hippocampal CA1 pyramidal neurons in the presence of PNU-120596 and physiological levels of
choline. In the absence of choline and PNU-120596, but in the presence of an inhibitory cocktail containing 20 mM gabazine, 15 mM DNQX, 50 mM
AP-5, 10 mM atropine and 40 mM picrotoxin, hippocampal CA1 pyramidal neurons did not exhibit any spontaneous activity in current-clamp
experiments (A). Addition of 10 mM choline plus 2 mM PNU-120596 to ACSF for at least 20 min elicited step-like voltage deviations in current-clamp
(B) and step-like current-deviations in voltage-clamp (C). Traces shown in B and C were recorded from the same CA1 pyramidal cell ,1 min apart.
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this study tested and confirmed the hypothesis that in the presence
of PNU-120596, physiological levels of choline (,10 mM) become
effective in activation of native functional a7* nAChRs expressed
in hippocampal CA1 pyramidal neurons in relatively low densities.
In the presence of PNU-120596, physiological concentrations of
choline were found to elicit a weak persistent activation of CA1
pyramidal a7* nAChRs and enhance the excitability of CA1
pyramidal neurons – effects that in in vivo settings may produce
neuroprotection [14,22,62,63] and cognitive benefits [11,64].
In the initial series of experiments, focal pressure application of
0.5–1 mM choline was used to demonstrate that: 1) The majority
of hippocampal CA1 pyramidal neurons express functional a7*
nAChRs; 2) A lack of responsiveness of some hippocampal CA1
pyramidal neurons to focal application of 0.5–1 mM choline in the
absence of PNU-120596 does not imply a lack of expression of
functional a7* nAChRs in these neurons, but may indicate a lack
of detection of a7* nAChR-mediated currents by patch-clamp
electrophysiology; and 3) PNU-120596 can serve as a powerful
tool for detection of low level expression and activation of
functional a7* nAChRs such as those expressed in hippocampal
CA1 pyramidal neurons.
To model the effects of endogenous choline on CA1 pyramidal
a7* nAChRs and neurons, physiological concentrations of choline
(i.e., ,10 mM) were added to ACSF and whole-cell voltage- and
current-clamp recordings were conducted in the presence and
absence of 2–5 mM PNU-120596 (Figures 4–5). These experi-
ments revealed that in the presence of PNU-120596 and 10 mM
choline, low densities of expression of CA1 pyramidal a7*
nAChRs generate persistent step-like currents which cause
transient depolarizations and occasionally, may trigger bursts of
action potentials (Figure 5). It is this capability of as few as only
one individual functional a7* nAChR to depolarize and excite the
entire neuron that makes it possible for a low density expression of
functional a7* nAChRs to be effective in enhancing the
excitability of hippocampal CA1 pyramidal neurons in the
presence of PNU-120596. Therefore, high levels of expression of
CA1 pyramidal a7* nAChRs and synchronization of their activity
Figure 6. Washout rates of choline and PNU-120596 in hippocampal slices. To evaluate the rates of washout of choline and PNU-120596 in
hippocampal slices, 0.5 mM choline and 5 mM PNU-120596 were added to ACSF for ,1 hr and step-like current deviations were recorded as controls
(Aa and Ca). One of the compounds (i.e., choline or PNU-120596) was then removed from ACSF while the other remained. When PNU-120596 was
removed from the mix (Ab–Ac), the frequency of step-like current deviations (events/min) dropped exponentially with the time constant, 25.9 min
(n=5, A–B). When choline was removed from the mix (Cb–Cc), the frequency of step-like current deviations also dropped exponentially, but with the
time constant, 9.9 min (n=5, C–D), i.e., ,2.6 times faster.
doi:10.1371/journal.pone.0013964.g006
In some current-clamp experiments, step-like voltage deviations elicited by 10 mM choline plus 2 mM PNU-120596 triggered full action potentials (D).
Action potentials shown in F) and in the framed insert to D) were truncated. Traces shown in D and E were obtained from the same cell ,1 min apart.
Similar results were obtained when 10 mM choline plus 5 mM (instead of 2 mM) PNU-120596 were applied to ACSF (F–G and Table 1). Traces shown in
F and G were recorded from the same cell ,1 min apart. Short horizontal bars in front of voltage traces correspond to the membrane voltage
of 260 mV.
doi:10.1371/journal.pone.0013964.g005
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physiological concentrations of choline plus PNU-120596 on CA1
pyramidal neurons. This may be important because deficits in
activation of hippocampal a7* nAChRs have been linked to certain
cognitive disorders and enhancing a7* nAChR activation by
systemic administration of nicotinic agonists has been shown to
produce neuroprotection and cognitive benefits [15,16,17,18,19,
21,28,29,30,57,65]. For example, a weak butpersistent activation of
a7* nAChRs can be achieved with low concentrations of nicotinic
agonists (e.g., ,1–6 mM 4OH-GTS-21 (i.e., 3-(4-hydroxy, 2-
methoxy-benzylidene)anabaseine), a selective a7 nAChR agonist
[56,66]) and has been shown to be neuroprotective in the NGF/
serum-withdrawal toxicity model in pheochromocytoma-12 cells
expressing functional a7* nAChRs [22]. Therefore, the results of
this study suggest that in the presence of PNU-120596, endogenous
choline may produce a weak but persistent activation of functional
a7* nAChRs in hippocampal CA1 pyramidal neurons and thus,
mayactasa potenttherapeutic agentwith potentialneuroprotective
and cognition-enhancing properties.
In the absence of PNU-120596, the mean open time of
hippocampal a7* nAChRs is very short (,100 ms, [54]) and
therefore,onlya highlysynchronizedactivityofa7*nAChRscanbe
confidently detected in voltage-clamp whole-cell experiments.
Indeed, in this study, fairly synchronous, although small, responses
were occasionally observed when high concentrations of choline
(0.5–1 mM) were focally applied via a picospritzer pipette to
recorded CA1 pyramidal neurons (Figure 1D). A lack of substantial
delay between pressure applications of choline and whole-cell
responses of CA1 pyramidal neurons suggests that at least some
pyramidal a7* nAChRs were expressed somatically (Figures 1D–E
and 2E). However, when considerably lower concentrations of
choline (e.g., 10 mM) were administered to ACSF in the absence of
PNU-120596, responses of pyramidal a7* nAChRs were not
detectable in whole-cell experiments (Figure 4A). By contrast, in the
presence of PNU-120596, 10 mM choline applied to ACSF elicited
clearly detectable responses (Figures 4B and 4D). These effects are
directly attributable to the synergistic action of 10 mM choline and
2 mM PNU-120596 allowing sub-threshold concentrations of
choline to activate a7* nAChRs [43]. The mean open time of
current deviations elicited by 10 mM choline in the presence of
2–5 mM PNU-120596 was estimated to be ,1.0 s (Table 1).
Therefore, in the presence of PNU-120596, a weak a7* nAChR
activity has a better chance of being detected in voltage- or current-
clamp whole-cell experiments than in the absence of PNU-120596,
and the synchronization of a7* nAChR activity is not necessary for
detection. Indeed, co-administration of 10 mM choline and 2–5 mM
PNU-120596 elicited clearly detectable step-like whole-cell respons-
es in voltage- and current-clamp experiments (Figures 4 and 5).
These responses were completely and reversibly blocked by 20 nM
MLA supporting the activation of a7* nAChRs (Figure 4E–F).
Intriguingly, current and voltage deviations recorded in voltage-
and current-clamp, respectively, in the presence of 10 mM choline
plus 2–5 mM PNU-120596 were step-like and thus, reminiscent of
single ion channel openings similar to step-like responses observed
previously in hypothalamic tuberomammillary neurons which in
contrast to hippocampal CA1 pyramidal neurons express very
high densities of functional a7* nAChRs [43]. Therefore, it is
likely that step-like responses elicited by synergistic action of
10 mM choline and 2–5 mM PNU-120596 result from openings of
individual a7* nAChR ion channels detectable in whole-cell
patch-clamp experiments.
Detecting activity of individual a7* nAChR ion channels in
whole-cell patch-clamp experiments appears to be possible if the
probability of ion channel openings is sufficiently low; and if the
channels remain open for a prolonged period of time during which
the ionic gradient across the membrane and thus, the ionic
current, remain relatively constant. These requirements appear to
be fulfilled for a7* nAChRs activated by physiological concentra-
tions of choline in the presence of 1–5 mM PNU-120596 in
hippocampal CA1 pyramidal neurons (this study), hippocampal
CA1 interneurons (Kalappa and Uteshev, unpublished observa-
tions) and hypothalamic TM a7* nAChRs [43]. In fact, the
probability of openings (Popen)o fa7* nAChRs expressed in TM
neurons has been estimated to be so low that in the presence of
10 mM choline plus 1 mM PNU-120596, only NTMPopen,0.27
a7* nAChR ion channels appeared to be open in the entire TM
neuron at any given time [43], where NTM is the total number of
detectable a7* nAChRs in a TM neuron.
In this study, the mean amplitude of current deviations and the
mean net charge per min generated by pyramidal a7* nAChR ion
channels in response to 10 mM choline plus 2 mM PNU-120596
were estimated to be ,5.5 pA (Figure 4H) and ,9.3 pC/
min=0.16 pA (Table 1). Therefore, under these conditions, the
mean number of a7* nAChR ion channels opened in the entire
hippocampal CA1 pyramidal neuron at any given time would be
estimated to be NpyrPopen,0.029 (=0.16pA/5.5pA), where Npyr is
the total number of detectable a7* nAChRs in a pyramidal
neuron. Note that in experiments with TM neurons, 10 mM
choline plus 1 mM PNU-120596 were used [43], whereas in this
study, the concentration of PNU-120596 was increased to 2 mM
because of the substantially lower levels of expression of functional
a7* nAChRs in hippocampal CA1 pyramidal neurons compared
to TM neurons. However, the exact subunit compositions of
functional a7* nAChRs expressed in CA1 pyramidal and TM
neurons remain unknown and may be different.
Native a7* nAChRs are highly permeable to Ca
2+ ions with the
permeability ratio PCa/PNa ,6.0 [67,68]. This value translates
into the fractional Ca
2+ current, Pf(a7*),10%, at 260 mV [68].
Therefore, the persistent activation of CA1 pyramidal a7*
nAChRs in the presence of 10 mM choline plus 2 mM PNU-
120596 would be expected to result in a persistent influx of Ca
2+
ions at a rate of ,0.016 pA (i.e., 10% of 0.16 pA). Although small,
this persistent Ca
2+ current may be physiologically relevant and
support neuroprotection [14,16,21]. Moreover, if injected in a
small volume of a pre-synaptic terminal expressing a7* nAChRs, it
may prime the terminal for plastic changes and thus, may assist in
modulation of neurotransmitter release. However, a possibility
that this relatively low, but persistent, rate of Ca
2+ influx is
cytotoxic cannot be presently ruled out.
One limitation of this study is that only relatively short-term
effects (,3 h) were investigated. Prolonged exposure of CA1
pyramidal a7* nAChRs to choline and PNU-120596 may cause
neurotoxicity due to a decrease in receptor desensitization and the
high Ca
2+ permeability of a7* nAChRs. Another limitation is that
all experiments in this study were conducted at room temperature
and the results may be somewhat altered by physiological
temperatures. One additional limitation comes from the fact that
in this study pyramidal neurons were pharmacologically isolated
and the majority of inhibitory (glycine/GABAA) and excitatory
(AMPA/NMDA) inputs were blocked by an inhibitory cocktail
(see Methods). Finally, the number of step-like current deviations
may have been underestimated because not all openings of
individual a7* nAChR ion channels may have been detectable in
whole-cell experiments. For example, responses of a7* nAChRs
located in distal dendritic regions may not have been detected
even in the presence of PNU-120596, due to electrotonic filtering.
As a result, the estimated value of NpyrPopen may have been
somewhat underestimated.
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PLoS ONE | www.plosone.org 13 November 2010 | Volume 5 | Issue 11 | e13964Hippocampal CA1 pyramidal neurons directly contribute to
generation of the hippocampal output and express two predom-
inant types of pre- and post-synaptic functional nAChRs: a7- and
a4b2-containing. The location and timely activation of these
receptors by pressure-applied ACh have been shown to modulate
and determine the sign of synaptic plasticity and the hippocampal
output [38,69]. CA1 pyramidal neurons receive inhibitory
GABAergic inputs from CA1 interneurons that express high
densities of a7* nAChRs (Figure 3B–C; [33,35,70]). CA1
interneurons may directly inhibit CA1 pyramidal neurons via
GABAergic synaptic inputs, or may excite CA1 pyramidal neurons
by inhibiting other CA1 interneurons (i.e., via disinhibition) [69].
Although PNU-120596 would be expected to enhance activation
of a7* nAChRs in pyramidal neurons and interneurons propor-
tionally (Figure 3), the net effect of this activation remains unclear
and is likely to be concentration-dependent. Moreover, in the
presence of PNU-120596, the activation of a7* nAChRs by ACh
would be expected to be substantially enhanced, while the
activation of non-a7* nAChRs should remain unchanged.
Therefore, in the presence of PNU-120596, the net effect on the
hippocampal output of activation of CA1 a7* nAChRs will likely
depend on the strength, timing and location of cholinergic
terminals and the relative densities of expression of pre- and
postsynaptic a7* and non-a7* subtypes of nAChRs, as discussed
previously [38,69]. In the present study, the net effect of activation
of CA1 a7* nAChRs was not investigated, as the majority of
excitatory and inhibitory inputs to pyramidal neurons were
blocked by an inhibitory cocktail (see Methods) and the effects
of activation of muscarinic AChRs were eliminated by using
choline and atropine. However, future studies may use the
presented in this study protocols to answer an important question
as to how a concurrent activation of CA1 pyramidal neurons and
CA1 interneurons by physiological concentrations of choline and
1–5 mM PNU-120596 affects the excitability of pyramidal neurons
and thus, the hippocampal output.
Although hippocampal CA1 pyramidal neurons express func-
tional a7* nAChRs, it remains to be determined whether
cholinergic terminals from the basal forebrain directly innervate
these neurons by establishing functional cholinergic a7* nAChR-
containing synapses, or activate pyramidal a7* nAChRs indirectly,
i.e., via volume transmission. It is also unknown whether
endogenously released ACh can reach pyramidal a7* nAChRs
at concentrations sufficient for generating physiologically signifi-
cant effects in the absence or presence of PNU-120596.
Nevertheless, the presented results support the hypothesis that
despite low densities of expression of functional a7* nAChRs in
hippocampal CA1 pyramidal neurons, in the presence of PNU-
120596 endogenous choline may persistently activate these
receptors and enhance the excitability of hippocampal CA1
pyramidal neurons in the absence of exogenous nicotinic agents
and endogenously released ACh. Therefore, in the presence of
PNU-120596, endogenous choline may serve as an efficacious
therapeutic agent in cholinergic therapies aimed at recovering the
deficiency in hippocampal a7* nAChR activation. Treatments
involving endogenous choline may also be safer than those
involving exogenous a7* nAChR agonists.
The expression of functional a7* nAChRs in brain tissues can
be estimated by [
125I] a-bungarotoxin binding, a selective a7*
nAChR antagonist [71]. The results of [
125I] a-bungarotoxin
binding in the hippocampal CA1 pyramidal region demonstrated
that the level of expression of a7* nAChRs is age-dependent [71],
peaks on postnatal days 2–5 (i.e., P2–5) and then declines to the
adult level by P20. In the present study, the majority of
experiments were conducted using P22–26 rats, therefore the
expression of functional hippocampal a7* nAChRs was near its
young adult levels [71]. Interestingly, only ,10% of hippocampal
a7 proteins are surface-expressed [32] and therefore, the CA1
hippocampal region may contain a large pool of unused a7
proteins. It is intriguing to speculate that under certain
endogenous conditions this pool of dormant a7 proteins can be
recruited to become functional and cell surface-expressed. It is also
feasible that certain endogenous compounds are capable of
enhancing a7* nAChR function in a manner similar to PNU-
120596. Finding these endogenous conditions and mechanisms of
regulation of a7* nAChR surface expression and function in the
hippocampus and other brain regions may have a tremendously
positive impact on the future of cholinergic therapies aimed at
restoring and boosting cognitive performance.
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